Mission Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-2,058
Closed -$279K 533
2021
Q2
$279K Buy
2,058
+41
+2% +$5.39K 0.01% 415
2021
Q1
$274K Buy
+2,017
New +$302K 0.02% 378

Other funds holding XBI

Mission Wealth Management's XBI Position: Q3 2021 in Review

Mission Wealth Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2021, closing a stake of 2,058 shares — an estimated $279K sold.

Mission Wealth Management first reported a position in XBI in Q1 2021 and held it in 2 quarters. The position peaked at $279K in Q2 2021. 635 funds tracked by Wall St. Rank hold XBI as of Q3 2021.

  • Mission Wealth Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2021 after selling out during the quarter.
  • Mission Wealth Management sold 2,058 State Street SPDR S&P Biotech ETF shares in Q3 2021, an estimated $279K.
  • Mission Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and held it in 2 quarters.
  • Mission Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $279K in Q2 2021.
  • 635 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2021.

Based on Mission Wealth Management's 13F filing for Q3 2021, filed 5 Nov 2021.